- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05139771
EndoArt® Implantation in Subjects With Chronic Corneal Edema
An Open-label Multicenter Phase 2 Clinical Safety Investigation of the EndoArt® Implantation in Subjects With Chronic Corneal Edema
The EndoArt® is intended to be used as an endothelial prosthesis in patients with chronic corneal edema.The EndoArt® (Artificial Endothelial layer) is a permanent implant, constructed of a clear, transparent, foldable, biologically compatible copolymer of hydroxyethyl methacrylate and methyl methacrylate. The peripheral surface of the EndoArt® has either one or more marks, to ensure the correct orientation of the implant. The device serves as a physical barrier blocking the influx of water from the AC of the eye into the cornea due to dysfunctional corneal endothelial layer. Together with evaporation from the anterior surface of the cornea it maintains corneal hydration and clarity.
The EndoArt® device is CE marked approved (approved for marketing by the European regulatory authority).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective, multicenter, open-label, phase 2 clinical investigation assessing safety of EndoArt® implantation, in subjects with chronic corneal edema. Safety will be assessed by evaluating the rate of adverse events and adverse device effects throughout the study period. Exploratory efficacy endpoints will be assessed by measuring the change in corneal thickness from baseline, change in pain score from baseline and changes in visual acuity. Time to, and rate of, post-surgical rebubbling to facilitate adhesion of the device will be explored.
Subjects with chronic corneal edema that meet the inclusion/exclusion criteria will be the study target population. The study will encompass a total of up to 80 subjects who will complete the Protocol follow-up schedule. For the Primary endpoint, the frequency and severity of device related adverse events, from patient entry through the 6-month follow-up period will be analyzed. Adverse events will be assessed on a continuous basis and will continue to be collected for 12 months.
This clinical investigation is conducted in up to 12 (twelve) clinical sites in Europe (Germany, France, and Netherlands), Mexico, India and Israel. Additional sites may be considered.
This clinical investigation has been designed to provide continuous clinical evidence for the EndoArt® as part of its clinical follow up program.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Brest, France, 29200
- Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)
-
Paris, France
- Hôpital Fondation A. de Rothschild
-
-
-
-
-
Tbilisi, Georgia
- High Technology Medical Center, University Clinic
-
Tbilisi, Georgia
- Akhali Mzera Eye Clinic
-
Tbilisi, Georgia
- Caucasus Medical Center (CMC)
-
Tbilisi, Georgia
- Davinci Eye Medical Center
-
-
-
-
-
Heidelberg, Germany
- International Vision Correction Research Centre (IVCRC) Universitätsklinikum Heidelberg
-
-
-
-
Tamil Nadu
-
Tirunelveli, Tamil Nadu, India, 627003
- Dr Agarwal's Eye Hospital
-
-
Telangana
-
Hyderabad, Telangana, India, 500034
- L V Prasad Eye Institute
-
-
-
-
-
Haifa, Israel
- Rambam Medical Center
-
Tel Aviv, Israel
- Assuta HaShalom
-
-
-
-
-
Amsterdam, Netherlands
- Amsterdam MC (AMC)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Individuals must meet the following inclusion criteria at screening visit:
- Male or Female subjects 40-85 years of age.
- Have chronic corneal edema (for a minimum of 3 months) secondary to endothelial dysfunction.
- Have corneal thickness >600μm by OCT.
- Have best corrected distance visual acuity 6/19 (20/63) or worse (equivalent ETDRS= 60 letters) with subjective symptoms of impaired visual function.
- Subject with posterior pseudophakia and stable IOL.
- Willing and able to understand and sign informed consent prior to any study related procedure.
- Willing and able to follow study instructions (e.g., to lay on one's back for 4 hours post op), able to self-administer or have caregiver available to administer eyedrops as required by the protocol for the duration of the study, and able to attend study visits/assessments for the duration of the study.
Exclusion Criteria:
Individuals for participation will be ineligible for the study if any of the following conditions apply:
- History of ocular Herpetic keratitis.
- Scarred cornea resulting in visual impairment with intact endothelium (cell density ≥ 1500).
- History of posterior vitrectomy.
- Post PKP
- Have an irregular posterior cornea (e.g., post trauma).
- Have a current infection of the cornea.
- Have band keratopathy and/or limbal stem cell deficiency.
- Have clinically severe dry eye disease which needs more than 4 drops of lubricant per day.
- Phthisis bulbi or subject is at risk of developing phthisis.
- Subject with medically uncontrolled high intra ocular pressure.
- Aphakia.
- Anterior chamber IOL or fixated anterior chamber IOL.
- Pseudophakodonesis.
- Have large iris defect which could compromise intraoperative air bubble formation
- Have undergone corneal refractive surgery.
- History of neurotrophic cornea.
- History of recurrent corneal erosion or persistent epithelial defect.
- IridoCorneal Endothelial (ICE) Syndrome or any rare disease/ syndrome creating anatomical or physiological anomalies of the anterior chamber (e.g., corectopia).
- Recurrent posterior, intermediate or anterior uveitis.
- Subject receiving regular intravitreal injection
- Currently participating or have participated in an investigational study, other than this study, within the past 60 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: EndoArt® Artificial Endothelial Layer
EndoArt® is intended to be used as an endothelial prosthesis in patients with chronic corneal edema.
One arm - all subjects will be implanted with EndoArt®.
|
Implantation of EndoArt® is similar to other anterior segment surgical procedures such as DSAEK/DMEK.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The frequency of device related adverse events (safety)
Time Frame: 12 months
|
Adverse events will be assessed on a continuous basis from baseline until follow-ups completion.
|
12 months
|
The severity of device related adverse events (safety).
Time Frame: 12 months
|
Adverse events will be assessed on a continuous basis from baseline until follow-ups completion.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in central corneal thickness (CCT) postoperatively.
Time Frame: 6 months
|
Central Corneal Thickness (pachymetry) will be measured by anterior segment Optical Coherence Tomography (OCT).
|
6 months
|
Incidence of primary post-surgical detachment of the device.
Time Frame: 12 months
|
Post implantation device detachment
|
12 months
|
Rate of rebubbling post-op.
Time Frame: 12 months
|
Number of times that post implantation re-bubbling is done
|
12 months
|
Change in Best Corrected Distance Visual Acuity (BCDVA) from baseline.
Time Frame: 12 months
|
Visual acuity will be measured with ETDRS format charts.
|
12 months
|
Change in ocular pain score as assessed by a Visual Analogue Scale (VAS) from baseline.
Time Frame: 12 months
|
VAS is a horizontal line, 0-100 mm.
VAS score is determined by measuring in millimeters from the left hand end of the line to the point that the subject marks.
|
12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLI-E033
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Corneal Edema
-
Eye-yon MedicalCompletedCORNEAL EDEMAIsrael, Poland
-
Eye-yon MedicalCompletedCorneal EdemaIsrael
-
Tiedra Farmacéutica SLHospital Universitario Principe de AsturiasUnknown
-
Aurion BiotechRecruitingCorneal Edema | Corneal Endothelial DysfunctionUnited States, Canada
-
Eye-yon MedicalCompletedChronic Cornel EdemaNetherlands, Israel, Germany, Spain
-
Aurion BiotechCompleted
-
Nicole Fram M.D.RecruitingAnterior Chamber Inflammation | Ocular Pain | Corneal Edema | Corneal Defect | Corneal Staining | Visual Outcome | CME - Cystoid Macular EdemaUnited States
-
Prince of Songkla UniversityCompletedIntraocular Pressure | Corneal EdemaThailand
-
Kowa Research Institute, Inc.CompletedA Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract SurgeryCorneal Edema After Cataract SurgeryUnited States, Puerto Rico
-
Rabin Medical CenterUnknownCorneal Edema | Visual AcuityIsrael
Clinical Trials on THE ENDOART® IMPLANTATION (Artificial Endothelial layer)
-
Eye-yon MedicalCompletedChronic Cornel EdemaNetherlands, Israel, Germany, Spain
-
R3 Vascular Inc.Cardiovascular Research Foundation, New York; Massachusetts General Physicians...RecruitingPeripheral Arterial Disease | Lower Extremity Claudication | Lower Extremity Ischemia | Atherosclerotic LesionCanada, Italy, Austria
-
Nurami Medical LtdCompletedCerebrospinal Fluid Leak | Dural TearSpain, Belgium, Poland, Czechia, Israel
-
Peijia Medical Technology (Suzhou) Co., Ltd.General Hospital of Shenyang Military Region; Shanghai Zhongshan Hospital; China... and other collaboratorsCompleted
-
Institut d'Investigació Biomèdica de BellvitgeSpanish Society of CardiologyCompletedMyocardial Infarction | Endothelial Dysfunction | Coronary Microvascular DiseaseSpain
-
Nanjing First Hospital, Nanjing Medical UniversityRecruiting
-
Sansum Diabetes Research InstituteJuvenile Diabetes Research FoundationCompletedType 1 Diabetes MellitusUnited States